Targeting MTAP-null cancer cells via selectiveinhibition of the PRMT5·MTA complex can improve tolerabilityrelative to nonselective PRMT5 inhibitors8−11 by limiting inhibition of PRMT5in normal cells. This evidence concerns the gene PRMT5 and cancer.